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MaCoronary angiography and percutaneous intervention rely on the use of iodinated intravascular contrast for vessel and
chamber imaging. Despite advancements in imaging and interventional techniques, iodinated contrast continues to pose
a risk of contrast-induced acute kidney injury (CI-AKI) for a subgroup of patients at risk for this complication. There has
been a consistent and graded signal of risk for associated outcomes including need for renal replacement therapy,
rehospitalization, and death, according to the incidence and severity of CI-AKI. This paper reviews the epidemiology,
pathophysiology, prognosis, and management of CI-AKI as it applies to the cardiac catheterization laboratory.
(J Am Coll Cardiol 2016;68:1465–73) © 2016 by the American College of Cardiology Foundation.T here have been many advancements in theﬁeld of interventional cardiology that haveresulted in a greater degree of patient safety
and have allowed an ever-increasing population at
risk to undergo diagnostic and interventional proce-
dures. Despite these steps forward, accurate imaging
of the coronary and peripheral vasculature remains
dependent on the use of intravascular injection of
iodinated contrast, which has well-known toxicities,
including contrast-induced acute kidney injury (CI-
AKI). This paper presents an update on the epidemi-
ology, pathogenesis, prognosis, and management of
CI-AKI as applied speciﬁcally to cardiac interven-
tional procedures.
EPIDEMIOLOGY
There are considerable sources of information indi-
cating that CI-AKI, and perhaps AKI overall, in
patients undergoing cardiac catheterization pro-
cedures has been declining over the past decade or
more. However, among those undergoing cardiac
surgery after coronary angiography, AKI and AKI
requiring dialysis (AKI-D) may be increasing. In 2012,
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of 31,532 patients and demonstrated that the rate
of AKI declined from 26.6% in 2000 to 19.7% in
2008 (26% reduction) using a deﬁnition consistent
with the Kidney Disease International Global
Outcomes Guidelines of a rise in serum creatinine
(sCr) $0.3 mg/dl or a $50% elevation from baseline
over the course of hospitalization. The National Car-
diovascular Data Registry Cath-PCI (N ¼ 985,737 who
underwent elective and urgent percutaneous coro-
nary intervention [PCI]) reported 69,658 (7.1%) cases
of CI-AKI (sCr rise $0.3 mg/dl) and 3,005 (0.3%) cases
of AKI-D (Figure 1) (2). Although in Figure 1, estimated
glomerular ﬁltration rate (eGFR) >60 ml/min/1.73 m2
is indicated to be normal, it may not be the case if it is
in the setting of a unilateral kidney or in a patient
with structural kidney disease (e.g., polycystic kidney
disease). As chronic kidney disease (CKD) progresses
and eGFR worsens, there is a sharp increase in the
rates of both CI-AKI and AKI-D, as shown in Figure 1.
The most important factors associated with a more
than doubling in the rates of CI-AKI and signiﬁcant
increases in the risk of AKI-D were ST-segment
elevation myocardial infarction (STEMI), eGFR
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ABBR EV I A T I ON S
AND ACRONYMS
ACEI = angiotensin-enzyme
inhibitor
ACS = acute coronary
syndromes
AKI-D = acute kidney injury
requiring dialysis
ARB = angiotensin-receptor
blocker
CI = conﬁdence interval
CI-AKI = contrast-induced
acute kidney injury
CKD = chronic kidney disease
Cr = creatinine
eGFR = estimated glomerular
ﬁltration rate
ESRD = end-stage renal
disease
HF = heart failure
HR = hazard ratio
LVEDP = left ventricular
end-diastolic pressure
MI = myocardial infarction
PCI = percutaneous coronary
intervention
RASi = renin-angiotensin
system inhibitors
sCr = serum creatinine
STEMI = ST-segment elevation
myocardial infarction
TAVR = transcatheter aortic
valve replacement
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1466contrast volumes among those with CI-AKI
ranged from 140 to 260 ml, similar to those
without CI-AKI (140 to 245 ml). Thus,
although rates of CI-AKI may have histori-
cally trended down over the past decade, the
risk is still formidable in the patients with the
greatest need for urgent PCI, including those
with STEMI and those developing cardio-
genic shock. In addition, the overall age in
this report from the Cath-PCI registry is 64.8
 12.2 years and thus is not reﬂective of the
growing numbers of the elderly undergoing
PCI currently and in the future. As the Cath-
PCI registry report elucidated, baseline
eGFR, STEMI, and cardiogenic shock are
strong predictors of CI-AKI and AKI-D after
PCI. Mehran et al. (3) developed and vali-
dated a comprehensive risk prediction score,
which also included age, hemoglobin, pre-
existing CKD, contrast volume, need for
intra-aortic balloon counterpulsation, and
other variables, in order to anticipate the rate
of CI-AKI, as well as the need for renal
replacement therapy. Although this tool can
be used for quality reporting and other
functions, it is not helpful before the proce-
dure because it incorporates variables that
can only be known after the case is
completed in the catheterization laboratory.
For pre-procedural counseling, the most
useful parameters are the eGFR and presence
of diabetes. In general, eGFR <60 ml/min/
1.73 m2 with diabetes elevates the risk ofCI-AKI sufﬁciently above the baseline of w5% to
w10%; thus, appropriate counseling and preventive
measures are warranted to mitigate this potential
adverse consequence of angiography.
PATHOPHYSIOLOGY
All forms of iodinated contrast are highly water-
soluble carbon-based benzene rings that exist as
monomers with 3 iodine atoms attached or as dimers
with 6 iodine atoms attached. The most common
types of contrast agents used today for intravascular
injection are either iso-osmolar (approximately 290
mOsm/kg) iodixanol, which is a dimer, or low-
osmolar (700 to 850 mOsm/kg) nonionic monomers
(iohexol, iomeprol, iopamidol, iopromide, ioversol,
ioxilan) (4). High-osmolar contrast agents (1,200
mOsm/kg or higher) are no longer used for cardiac
catheterization. The iodine concentration of these
products is similar (320 to 270 mg I/ml). However,
when administered in the blood at 37C, the11.8 centipoise (cps) viscosity of iodixanol is signiﬁ-
cantly higher than that of iohexol, at 6.3 cps, the
lowest in the low-osmolar category. In a rat model,
the viscosity in urine can be considerably greater
with iodixanol (5). Among these 3 physiochemical
properties, the higher the osmolality or the particle
concentration in solution, the greater the vascular
symptoms of warmth and pain during injection, as
well as CI-AKI (6). When iodinated contrast is injec-
ted into the systemic arterial circuit, there is a tran-
sient endothelium-dependent vasodilation mediated
by release of nitric oxide, followed by arteriolar
vasoconstriction lasting for several seconds to mi-
nutes in the peripheral circulation (Figure 2) (7). In
the renal arcade of blood vessels that subdivide into
the afferent glomerular arteriole serving the glomer-
ulus, efferent arteriole dividing and forming the
peritubular network, and ﬁnally the vasa recta, the
transient dilation can be followed by a period of
sustained vasoconstriction that lasts for several
hours (7). When there is a reduced renal parenchymal
mass and fewer nephrons in the setting of CKD and
among those with diabetes, the reduction in renal
blood ﬂow can be sufﬁciently sustained to impair
oxygenation to the outer medulla, resulting in
ischemia to the proximal and distal tubules.
Furthermore, the water-soluble contrast is readily
taken up by the apical surface of proximal tubular
cells (pumps, bystander endocytosis) and out of the
basal-lateral surface into the tubulointerstitial space
(8). Tubular cells undergo swelling, blebbing, and
apoptosis, as shown in Figure 2. As a result, there is
stasis of contrast within the kidneys after the proce-
dure is completed. Of note, 3-hydroxy-3-methyl-glu-
taryl-CoA reductase regulates the production of
isoprenoid pyrophosphates, which in turn play a key
role in the proper function of guanosine
triphosphate-binding protein-mediated endocytosis
(9). In an in vitro model, statins inhibit endocytosis in
renal tubular cells (10). This is the putative, beneﬁcial
mechanism of action attributed to statins, which will
be discussed later. With high concentrations of
contrast within and surrounding renal tubular cells,
there is direct cellular toxicity with loss of the tubular
brush border, breakdown of desmosomes, loss of cell
membrane integrity, and sloughing of material into
the urinary tubular space (Tamm-Horshfall protein),
which promotes further stasis of contrast in the
urine, enabling more movement of contrast into the
tubulointerstitial space, where there is no ready form
of clearance. Patients with CKD and diabetes have
been reported to have persistent nephrograms where
contrast can be seen within the kidneys for up to
8 days after contrast administration (11). The
FIGURE 1 Incidence of CI-AKI and New ESRD Requiring Dialysis From the
ACC Cath-PCI Registry
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1467combination of both ischemic and chemotoxic injury
to the proximal tubules triggers a process called
tubuloglomerular feedback, which signals the
glomerulus to reduce ﬁltration, and hence the rise in
the plasma concentration of creatinine (Cr) is seen
approximately 24 to 48 h after there has been a sig-
niﬁcant reduction in ﬁltration (12). Newly available
urine markers of tubular damage (Figure 3) can
elevate within a few hours of tubular injury
(neutrophil gelatinase-associated lipocalin, fatty-acid
binding protein, and cell-cycle arrest markers
[insulin-like growth factor binding protein-7, tissue
inhibitor of metalloproteinase-2]) (13). These markers
hold promise for the detection of subclinical CI-AKI,
as well as early detection of more severe cases,
where future treatments may be applied before there
is cessation of renal ﬁltration and a drop in urine
output.
Iodinated contrast does not injure the glomerulus;
therefore, no hematuria is seen. Contrast is water
soluble and freely ﬁltered; however, its water solu-
bility allows relatively easy reabsorption by the
proximal tubular cells, where it causes cellular dam-
age (8). Recent evidence suggest that as renal tubular
cells are damaged, the mitochondria release intra-
cellular catalytic or unbound iron, which serves as the
catalyst in the Haber-Weiss and Fenton equations to
drive oxidative stress and the production of the
dangerous hydroxyl radical (14). A similar process is
accentuated by exposure of iron-rich myoglobin in
the setting of rhabdomyolysis, as well as heme in the
setting of cardiac surgery (15). Of interest, the 3 ways
of reducing these oxidative stress reactions are: 1)
reduce temperature (as is done during cardiac sur-
gery); 2) alkalinize the environment; or 3) remove the
substrate and or catalyst (14). Additionally, alkalin-
ization reduces the precipitation of Tamm-Horsfall
protein in the tubular lumen (16).
Subclinical CI-AKI may occur in every patient
exposed to iodinated contrast. Because there is a
robust tubular repair capability in healthy subjects,
this process may not have any clinical consequences
(17). However, in patients with CKD and diabetes
mellitus, who have a reduced number of functioning
nephrons and an impaired ability to regenerate
tubular epithelial cells, routine cardiac procedures
using average doses of iodinated contrast can cause
CI-AKI that is clinically important. The natural history
of acute tubular injury follows a time course of
approximately 8 to 10 days, with recovery and
regeneration of tubular cells from within the tubule
structure. However, with each exposure of contrast,
there may be sufﬁcient destruction to some nephrons
that recovery is not possible, and ultimately, there isloss of the functional unit, replaced by ﬁbrosis. Thus,
in those with few functioning nephron units and
advanced CKD (eGFR <30 ml/min/1.73 m2), CI-AKI can
result in such a relatively large proportional reduc-
tion in renal ﬁltration to yield azotemia, volume
overload, and hyperkalemia warranting renal
replacement therapy. In approximately one-half of
these cases, there is permanent end-stage renal
disease (ESRD), whereas in the other one-half, there
can be eventual recovery that allows some period of
dialysis-free survival.
With catheter administration of intra-arterial
contrast, there is the opportunity for microshowers
of atheroembolic material to the renal and systemic
circulation. Because the kidneys receive 25% of
cardiac output, it has been hypothesized that micro-
embolism not detected clinically accounts for some
portion of CI-AKI. The relative contribution of renal
atheroemboli may be greater in CI-AKI cases after
transcatheter aortic valve replacement (TAVR), where
the proportion of cases that result in severe acute
kidney injury appears to be higher than in reports
from PCI registries. However, a pooled analysis has
suggested that TAVR is associated with a lower risk of
AKI compared with surgical valve replacement (18). In
studies of patients with similar levels of renal func-
tion and contrast doses given in the venous system,
there are consistently lower rates of CI-AKI, largely
because there is no opportunity for atheroembolism
and possibly because of a greater admixture of
contrast in the blood pool before the kidneys are
FIGURE 2 Pathogenesis of CI-AKI
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This ﬁgure demonstrates that from the point of injection into the coronary arteries, iodinated contrast triggers a series of hemodynamic responses and direct
cellular injury as it reaches the kidneys. Adapted with permission from Brown and McCullough (33). CI-AKI ¼ contrast-induced acute kidney injury.
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1468exposed. Additionally, acute coronary syndrome
(ACS) and, in particular, STEMI patients have been
observed to have nearly double the rates of CI-AKI.
This may be due to neurohormonal activation,
release of catalytic iron from the heart, inadequate
opportunity for volume expansion, and greater rates
of hemodynamic instability.
PROGNOSIS
Studies have consistently reported higher rates of
virtually every complication after PCI in those who
experience CI-AKI. Direct complications of CI-AKI can
include volume overload and hyperkalemia that
require urgent dialysis, the development of ESRD,
and death. However, CI-AKI is a clinical marker for
individuals who are more frail, and susceptible to
medical and procedural complications. In the report
from the Cath-PCI registry, the rates of recurrent
myocardial infarction (MI), major bleeding ($3 g/dl
decrease in hemoglobin, transfusion of whole packedred blood cells, or an intervention to stop the
bleeding within 72 h of the procedure), and death in
those not on dialysis, and with no evidence of CI-AKI
after contrast administration were 2.1% MI, 1.4%
bleeding, 0.5% death. These outcomes were all
signiﬁcantly higher in those with CI-AKI (3.8% MI,
6.4% bleeding, 9.7% death) and considerably greater
in those with AKI-D (7.9% MI, 15.8% bleeding, 34.3%
death). Although confounding by known variables,
such as older age, female sex, diabetes, severity of
coronary disease, left ventricular dysfunction, pre-
sentation as non-STEMI, STEMI, cardiogenic shock, or
cardiac arrest are the most likely explanation for
these higher rates of events, it is possible that acute
tubular injury triggers clinical events in other organs
on the basis of yet-to-be understood mechanisms.
MANAGEMENT
Principles of management include using volumes of
contrast that are as low as reasonably achievable
FIGURE 3 Anatomy of a Single Nephron and Location of Novel and Conventional Biomarkers of Renal Filtration and
Tubular Epithelial Cell Damage
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Markers of ﬁltration indicate transient reductions in glomerular function, whereas cell damage markers indicate cellular injury, and the 2
together have a poorer prognosis than either alone. Not all of these markers have been validated for CI-AKI. Cell cycle arrest markers are
TIMP2*IGFBP-7 (tissue inhibitor of metalloproteinase-2 and insulin-like growth factor binding protein-7). CI-AKI ¼ contrast-induced acute
kidney injury; GST ¼ glutathione S-transferase; IL ¼ interleukin; KIM ¼ kidney injury molecule; L-FABP ¼ L-type fatty-acid binding protein;
NAG ¼ N-acetyl-beta-D-glucosaminidase; NGAL ¼ neutrophil gelatinase-associated lipocalin.
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1469(ALARA) and selection of the least-toxic iodinated
contrast agent in the highest-risk patients
(Central Illustration). Low-osmolar contrast agents are
reasonable for moderate-risk patients and iso-
osmolar contrast is indicated for the highest-risk pa-
tients. In patients with high-risk proﬁles (eGFR
<30 ml/min/1.73 m2 with diabetes, heart failure [HF],
or urgent PCI for ACS), there is no absolutely safe
limit of contrast dose; hence, the most reasonable
approach is to maximize the beneﬁt to risk balance of
the procedure by performing revascularization and
then expectantly manage the CI-AKI to follow.
Contrast minimization can be achieved using in-line
devices in the contrast tubing manifold system that
work to reduce injection overshoot by the operator
(AVERT Plus System, Osprey Medical, Minnetonka,
Minnesota). This system is currently being tested
against expert operators in an attempt to re-
duce the incidence of CI-AKI (19). Avoiding leftventriculography and aortography are additional
strategies commonly used to reduce the overall
contrast dose.
Because iodinated contrast is water soluble, it is
amenable to prevention strategies that expand
intravascular volume and increase renal ﬁltration and
tubular ﬂow of urine into collecting ducts, and on into
the ureters and bladder. CI-AKI is responsive to
intravascular administration of isotonic crystalloid
solutions to enhance renal elimination of contrast via
the urine. There have been numerous randomized
trials comparing isotonic bicarbonate solutions to
intravenous saline, and in the largest and highest-
quality trials, there have been no differences in the
rates of renal outcomes (20,21). Hence, either isotonic
crystalloid solution is recommended, with some
guidance on the quantity of ﬂuid according to patient
factors. The POSEIDON (Prevention of Contrast Renal
Injury with Different Hydration Strategies) trial
CENTRAL ILLUSTRATION Algorithm for the Prevention and Management of CI-AKI
Assess Contrast-Induced Acute Kidney Injury (CI-AKI) risk
2eGFR 30–59 ml/min/1.73 m2eGFR <30 ml/min/1.73 m2
Throughout:
Good clinical practice:
Discontinue metformin, 
other nephrotoxic drugs, 
RAAS inhibitors
Throughout:
Good clinical practice as for
eGFR > 60 ml/min/1.73 m2
Before procedure:
Ensure statin use 
Pre-procedure IV volume
expansion**
During procedure:
LVEDP-guided intraprocedure
+ 4 hours post-procedure isotonic
crystaloid management
Low-osmolar contrast
Iso-osmolar contrast (iodixanol) if 
ACS, CKD=DM, HF, TAVI
As low as reasonably
achievable contrast volume
Post procedure:
Ensure statin use
Throughout:
Good clinical practice as for
eGFR > 60 ml/min/1.73 m2
Other strategies as for 
eGFR 30–59 ml/min/1.73 m2
Before procedure:
Consider hospital admission
Nephrology consultation
Dialysis planning*
Same intravenous volume
management as for
eGFR 30–59 ml/min/1.73 m2
During procedure:
Iso-osmolar contrast
(iodixanol)
Post procedure:
Measure renal damage markers
and daily serum creatinine
McCullough, P.A. et al. J Am Coll Cardiol. 2016;68(13):1465–73.
*Plans should be made in case CI-AKI occurs and dialysis is required. **IV isotonic crystalloid 3 ml/kg/h for 1 h before. Initial LVEDP-guided crystalloid: <13 mm Hg/
5 ml/kg/h  4 h; 13 to 18 mm Hg/ 3 ml/kg/h  4 h; >18 mm Hg/ 1.5 ml/kg/h  4 h. Renal damage markers: IGFBP-7*TIMP2 (NephroCheck), NGAL, L-FABP.
ACS ¼ acute coronary syndromes; CI-AKI ¼ contrast-induced acute kidney injury; CKD ¼ chronic kidney disease; DM ¼ diabetes mellitus; eGFR ¼ estimated glomerular
ﬁltration rate; HF ¼ heart failure; IGFBP-7*TIMP2 ¼ insulin-like growth factor binding protein-7 concentration multiplied by tissue inhibitor of metalloproteinase-2
concentration; IV ¼ intravenous; L-FABP ¼ L-type fatty-acid binding protein; LVEDP ¼ left ventricular end-diastolic pressure; NGAL ¼ neutrophil-associated lipocalin;
RAAS ¼ renin-angiotensin-aldosterone system; TAVI ¼ transcatheter aortic valve implantation.
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1471randomized 396 patients with eGFR <60 ml/min/1.73
m2 and 1 additional risk factor to a strategy of mea-
surement of left ventricular end-diastolic pressure
(LVEDP) and expanding plasma volume versus usual
care. Each group had standard-of-care of normal sa-
line 3 ml/kg for 1 h before cardiac catheterization. The
LVEDP-guided approach (Central Illustration) was
associated with more intensive ﬂuid administration
during and after the procedure, and was associated
with a reduction in CI-AKI (6.7% [12 of 178]) compared
with the control group (16.3% [28 of 172]; relative risk:
0.41, 95% conﬁdence interval [CI]: 0.22 to 0.79; p ¼
0.005). Intravenous ﬂuid was terminated prema-
turely because of concerns regarding volume over-
load in only 3 patients in each group. Even more
intensive management with intravenous crystalloid
with forced diuresis has been tested in a series of
randomized trials using a ﬂuid balance system that
measures and controls intravenous crystalloid vol-
ume with urine output (RenalGuard System, PLC
Medical Systems, Milford, Massachusetts). All of
these trials have demonstrated that elevation of urine
output to >150 ml/h before and during the procedure
reduces rates of CI-AKI (22). In a single-center trial,
112 consecutive patients undergoing TAVR were
randomly assigned to normal saline controlled by the
RenalGuard system with urine ﬂow initially
augmented by furosemide (RenalGuard group) or
normal saline-based usual care (control group). The
primary endpoint was the incidence of CI-AKI (Cr
rise $0.3 mg/dl or $50%) in the ﬁrst 72 h after the
procedure. The AKI rate was lower in the RenalGuard
group than in the control group (n ¼ 3 [5.4%] vs. n ¼
14 [25.0%], respectively; p ¼ 0.014). No case of in-
hospital AKI-D was reported. No signiﬁcant differ-
ences in terms of mortality, cerebrovascular events,
bleeding, and hospitalization for HF were noted in
either group at 30 days.
To date, no adjunctive pharmaceutical has been
demonstrated to effectively prevent or treat CI-AKI.
There has been a pattern of small, randomized trials
and meta-analyses of these trials showing beneﬁt with
a speciﬁc agent (e.g., N-acetylcysteine, ascorbic acid,
aminophylline, trimetazidine, fenoldopam, among
others), often with low event differences between the
groups and large effect sizes attributable to alpha er-
ror or imbalanced randomization (23,24). When sub-
jected to large randomized clinical trials, every agent
tested to date has failed to prevent and/or treat CI-
AKI. Thus, large clinical trials have an important role
in this ﬁeld. N-acetylcysteine is currently being tested
in a randomized factorial design with sodium
bicarbonate in a large (N ¼ 8,680) deﬁnitive trial
(PRESERVE [Prevention of Serious Adverse EventsFollowing Angiography]) (25). At the present time,
however, 2 chronic therapies may have an inﬂuence
on CI-AKI, despite being used for other reasons, sta-
tins and renin-angiotensin system inhibitors (RASi):
angiotensin-converting enzyme inhibitors [ACEI] and
angiotensin-receptor blockers [ARB]).
Statins appear in all observational and randomized
studies to date to protect against the development of
CI-AKI. Statins may be renoprotective via several
mechanisms, including inhibition of uptake of
contrast into renal tubular cells, attenuation of
endothelial dysfunction and oxidative stress, anti-
inﬂammation, antiproliferation of mesangial cells,
and protection of podocytes. In 2012, Li et al. (26)
performed a meta-analysis that again looked at the
beneﬁt of short-term high-dose statins in the pre-
vention of CI-AKI, which included 7 studies and 1,399
patients. They found a signiﬁcant improvement in the
incidence of CI-AKI, but no beneﬁt in AKI-D. The
PRATO-ACS (Protective effect of Rosuvastatin and
Antiplatelet Therapy On contrast-induced acute
kidney injury and myocardial damage in patients
with Acute Coronary Syndrome) trial analyzed the
role of rosuvastatin in statin-naïve patients for
preventing CI-AKI (27). They randomized 504 statin-
naive non-STEMI ACS patients undergoing PCI to
statin or no statin therapy. Statin patients received
rosuvastatin 40 mg on admission, then 20 mg daily,
whereas the control patients did not receive statins
during the hospitalization. At discharge, the statin
group continued treatment with 20 mg/day
rosuvastatin (10 mg/day for patients with GFR
<30ml/min/m2), whereas controls received 40mg/day
atorvastatin. CI-AKI was deﬁned as a rise in sCr by
0.5 ml/dl or 25% above baseline within 72 h of
receiving contrast. The study found the statin group
had a signiﬁcantly lower rate of CI-AKI than the no
statin group (6.7% vs. 15.1%; adjusted odds ratio:
0.38; 95% CI: 0.20 to 0.71; p ¼ 0.003). This beneﬁt was
signiﬁcant across all pre-speciﬁed risk categories. In
addition to the primary endpoint, multiple positive
secondary endpoints were noted. There was a
decrease in 30-day composite death, dialysis, MI,
stroke, or persistent renal damage in the statin group
(3.6% vs. 7.9%, respectively; p ¼ 0.036), as well as a
trend toward a decrease in death or MI at 6 months
(3.6% vs. 7.2%, respectively; p ¼ 0.07). Han et al. (28)
tested rosuvastatin in prevention of CI-AKI in 2,998
patients with diabetes and CKD who were undergoing
coronary or peripheral angiography with or without
intervention. Patients who were on statins previously
were asked to hold their statin for 14 days before the
procedure. Patients were randomized to statin ther-
apy or standard of care (no statin). The statin group
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1472received rosuvastatin 10 mg daily starting 2 days
before the procedure and continuing for 5 days. The
standard of care group and statin group resumed
statin therapy 3 days after intervention. CI-AKI was
deﬁned as an increase of sCr concentration
$0.5 mg/dl or 25% above baseline at 72 h. The statin
group had a signiﬁcantly lower incidence of CI-AKI
(2.3% vs. 3.9%; p ¼ 0.01). Additionally, a signiﬁ-
cantly lower rate of HF was noted in the statin group
at the 30-day follow-up (2.6% vs. 4.3%; p ¼ 0.02) (28).
RASi are proven therapies for hypertension and
HF, and are indicated to reduce the progression of
diabetic nephropathy. The chronic beneﬁcial effect of
RASi on the kidney is mediated, in part, by reduction
of intraglomerular pressure due to efferent glomer-
ular arteriolar dilation. This mechanism, however,
may be deleterious to the kidneys in the setting of
acute illness or in the setting of iodinated contrast,
where the ability to raise intraglomerular pressure/
ﬁltration via tubuloglomerular feedback may be
beneﬁcial in maintaining glomerular ﬁltration and
forward ﬂow of urine through the proximal tubules
and the remainder of the nephron. The most recent
trial to address this issue was the CAPTAIN (Angio-
tensin Converting Enzyme Inhibitor/Angiotensin Re-
ceptor Blocker and Contrast Induced Nephropathy
in Patients Receiving Cardiac Catheterization) trial,
which randomly assigned 208 patients with Cr
$1.7 mg/dl within 3 months or $1.5 mg/dl within 1
week before coronary angiography to hold RASi (ACEI
72.1% or ARB 27.9%) $24 h pre-procedure or continue
RASi. The primary outcome was the incidence of
CI-AKI, deﬁned as an absolute rise in sCr $0.5 mg/dl
from baseline and/or a relative rise in sCr $25%. At
48 to 96 h, CI-AKI occurred in 10.9% of RASi-held
compared to 18.4% of RASi-continued patients
(hazard ratio [HR]: 0.59; 95% CI: 0.30 to 1.19;
p ¼ 0.16). In a pre-speciﬁed secondary outcome, there
was a lower rise in mean sCr after the procedure in
patients who held ACEI/ARB (0.3  0.5 mg/dl vs. 0.1
 0.3 mg/dl; p ¼ 0.03). A clinical composite of death,
MI, ischemic stroke, congestive HF, rehospitalization
for cardiovascular cause, or need for dialysis peri-
procedural occurred in none of the RASi-held and
3.9% of the RASi-continued groups (HR: 0.11; 95% CI:
0.01 to 2.96; p ¼ 0.06). These data, combined with
reports from CKD trials, suggest that although RASi
are beneﬁcial chronically, either too intensive RASi
(ACEI þ ARB) or direct renin inhibition appears to
have excessive toxicity in the setting of hospitaliza-
tion, and probably in the setting of cardiac catheter-
ization and PCI as well (29,30). Thus, it appears to be
reasonable to hold RASi before coronary angiography
in moderate and above-risk patients.FUTURE DIRECTIONS
It appears that we are considerably invested in
ﬂuoroscopy and cineangiography in the world of
invasive cardiology for many years to come. Tech-
nology to minimize contrast by avoiding over-
injection and accurately recording contrast volumes
will provide some help as our procedures become
ever more complicated (31). This being considered,
novel forms of nontoxic radio-opaque contrast
would be welcomed; however, we are aware of no
such new molecular entities in development. At-
tempts to render iodine-based radiocontrast less
toxic are promising, particularly with the use of
cyclodextrin, which makes contrast stay in the uri-
nary space and less likely to penetrate the kidney
tissue and cause damage (32). Finally, the develop-
ment of cellular protectants continues to be an area
of interest and, despite the disappointing results
with n-acetyl cysteine, sodium bicarbonate, prosta-
glandins, fenoldopam, and other agents, there is
hope that an adjunctive agent could be administered
that would render the kidneys less susceptible to
damage, and possibly protect the heart and other
organs as well.
CONCLUSIONS
CI-AKI remains a concern for patients undergoing
cardiac interventional procedures utilizing intra-
vascular iodinated contrast. This form of renal
injury appears to be amenable to volume expansion
and to measures to increase urine ﬂow and re-
moval of highly water-soluble contrast. Minimizing
contrast by use of ALARA principles and strategies
to maximize the beneﬁt of contrast exposure (i.e.,
revascularization) are reasonable. Although no
adjunctive therapy is prophylactic or therapeutic
for CI-AKI, statin use appears to reduce the inci-
dence and severity of AKI, whereas continuation of
RASi appears to increase the risk for CI-AKI.
Further research is needed in the development of
less toxic contrast agents, as well as therapies that
can reduce cardiorenal complication of interven-
tional cardiovascular procedures. Such agents hold
the promise of improving long-term outcomes
by minimizing the hazards of intercurrent events,
such as ACS, and urgent and planned catheteriza-
tion procedures.
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